Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount recent data from the DUET trials describing baseline characteristics predictive of etravirine response
- Discuss the results of a study assessing the virologic response in patients treated with the combination of raltegravir, darunavir/ritonavir, and etravirine
- Describe the associated affects of maraviroc on CD4+ cell count increases when compared with placebo
- Explain the virologic outcomes associated with a switch from enfuvirtide to raltegravir
- Identify investigational NNRTIs in early stages of clinical development
Topics covered include:
- Patient Characteristics Predictive of Etravirine Response Include Baseline Viral Load and CD4+ Cell Count but not Sex or Race
- Correlating Etravirine and Darunavir Resistance to Patient Response: Week 24 Subgroup Analysis of DUET Trials
- GRACE Interim Analysis: The Role of Patient Sex and Race in Response to Darunavir/Ritonavir
- Etravirine Safety: Lack of Associated Fetal and Neurologic Toxicity but Increased Incidence of Rash
- Preliminary Safety and Efficacy Report on US Patients in the Etravirine Early Access Program
- Switch From Enfuvirtide to Raltegravir With Virologic Suppression
- TRIO: Week 24 Efficacy of Regimens Containing the Combination of Raltegravir, Etravirine, and Darunavir/Ritonavir
- MOTIVATE Subanalyses: Immunologic Affects Associated With CCR5 Inhibition and Virologic Response by Baseline Viral Load
- Pharmacokinetics of the Heat-Stable Ritonavir Tablet Formulation
- Update on Investigational Antiretroviral Agents: Rilpivirine, RDEA806, and IDX899